

61<sup>ST</sup> ANNUAL


# Denver **TB** Course (Hybrid Event)

APRIL 2-4, 2025






# TB Epidemiology

Amy Beeson, MD, FAAP  
April 2<sup>nd</sup>, 2025



**PUBLIC HEALTH  
INSTITUTE**  
AT DENVER HEALTH™





# Relevant disclosures

- None

# Objectives

- Review global and U.S. estimates and trends in TB infection, TB disease, DR-TB, and death from TB

# Objectives

- Review global and U.S. estimates and trends in TB infection, TB disease, DR-TB, and death from TB
- Describe biopsychosocial factors associated with TB infection and outcomes

# Objectives

- Review global and U.S. estimates and trends in TB infection, TB disease, DR-TB, and death from TB
- Describe biopsychosocial factors associated with TB infection and outcomes
- Discuss how TB epidemiology informs clinical decision making and elimination strategy

# TB infection estimates



- 25% of the world's population is infected with TB (1.7 billion people)


# TB infection estimates




- 25% of the world's population is infected with TB (1.7 billion people)
- 2-3% of the U.S. population is infected with TB (8-10 million people)
  - 14% among people born outside U.S.
  - 1% among people born in U.S.



## Global map of prevalence of latent TB infection, 2014



# Estimated prevalence of latent tuberculosis infection, by county, United States, 2011–2015




Haddad MB, Raz KM, Lash TL, Hill AN, Kammerer J, Winston CA, et al. Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011–2015. *Emerg Infect Dis*. 2018;24(10):1930-1933. <https://doi.org/10.3201/eid2410.180716>

# TB disease estimates




- TB is increasing globally since 2020
  - The rate of increase slowed in 2023
  - There is significant variability by region

# TB disease estimates



- TB is increasing globally since 2020
  - The rate of increase slowed in 2023
  - There is significant variability by region
- **TB is increasing in the U.S. since 2020**


# TB is increasing worldwide




10.8 million (134 cases per 100,000 persons)




## Estimated TB incidence rates, 2023






### Global estimates of TB incidence disaggregated by age group and sex (female in purple; male in orange), 2023




# TB is increasing in the United States



Provisional 2024 TB Data, United States, CDC, 4 March 2025

# Progress Towards TB Elimination, United States, 1982–2023



Reported Tuberculosis in the United States, 2023, CDC, data as of 17 July 2024



# DR-TB




- Globally, MDR-TB (total cases and proportion of all new cases) is estimated to be stable or slowly decreasing

# DR-TB




- Globally, MDR-TB (total cases and proportion of all new cases) is estimated to be stable or slowly decreasing
- In the U.S., MDR-TB is relatively stable (100 cases/year)


# Global DR-TB



**Estimated number of people who developed MDR/RR-TB (incident cases) in 2023, for countries with at least 1000 incident cases<sup>a</sup>**



# Number and Percentage of Multidrug-Resistant (MDR) TB Cases by History of TB, United States, 1993–2023





# Deaths from TB



Image: James Nachtwey (Tugela Ferry, KwaZulu-Natal, South Africa)

# Deaths from TB




- In 2023, TB *probably* caused more deaths globally than any other infection, and twice as many as HIV/AIDS
  - 1.25 million deaths (1.09 million among HIV-negative people)

# Deaths from TB



- In 2023, TB *probably* caused more deaths globally than any other infection, and twice as many as HIV/AIDS
  - 1.25 million deaths (1.09 million among HIV-negative people)
- **565 people in the U.S. died from TB in 2022**

# COVID-19 disruptions drove excess TB mortality



# Objectives

- Review global and U.S. estimates and trends in TB infection, TB disease, DR-TB, and death from TB
- Describe biopsychosocial factors associated with TB infection and outcomes



# Biopsychosocial model and TB



Image: Lewis Hine, taken January 1912 (Library of Congress)

# Biopsychosocial model and TB




Image: Carabayllo, Lima, Peru (Socios En Salud)




“There was no social revolution to accompany the scientific one. As a result, we now live in a world in which several different standards of care may be advocated for the same disease. For those with chronic infectious diseases, including tuberculosis and AIDS, those standards of care include excellent treatment for some, ineffective treatment for others, and no treatment for most. Ironically, perhaps, the reality that hundreds of millions live without any access to effective therapy at all serves to justify the setting of double standards, with the excuse that any care is an improvement over current conditions.”




# Model of TB



# Model of TB




# Model of TB





# Likelihood of progression declines over time




Timing and Predictors of Tuberculosis Incidence among Contacts

Michael Asare-Baah, Michael Lauzardo, Lori Johnston, Lina Dominique, Marie Nancy Séraphin


medRxiv 2024.11.02.24316631; doi: <https://doi.org/10.1101/2024.11.02.24316631>

# Percentage of TB Cases Among Non-U.S.–Born Persons by Years Since Arrival in the United States Prior to Diagnosis, 2023 (N=7,299)




Reported Tuberculosis in the United States, 2023, CDC, data as of 17 July 2024


# Model of TB



# Global estimates of the number of people with a new episode of TB (incident cases) attributable to five risk factors,<sup>a</sup> 2023



# Implementation challenges: MDR-TB in India



# Objectives

- Review global and U.S. estimates and trends in TB infection, TB disease, DR-TB, and death from TB
- Describe biopsychosocial factors associated with TB infection and outcomes
- Discuss how TB epidemiology informs clinical decision making and elimination strategy



# Case 1

A 40yo healthy man who immigrated to the U.S. from South Africa 1 month ago has a positive IGRA. He has no symptoms and chest x-ray is normal. He does not recall contact with anyone with an active TB diagnosis or symptoms. How do you counsel him about risk-benefit of preventive treatment?

- A. He is not at elevated risk as he does not recall a recent exposure; shared decision-making
- B. He is at risk of progression to active TB due to recent immigration from a high-burden country; treatment highly encouraged
- C. He is at risk of progression to active TB due to male sex; treatment highly encouraged

# Case 3

You are designing a program to eliminate TB in your state or region and are given \$100 million over 5 years. Where do you start?

# Additional references

Farmer P, Robin S, Ramilus SL, Kim JY. Tuberculosis, poverty, and "compliance": lessons from rural Haiti. *Semin Respir Infect.* 1991 Dec;6(4):254-60. PMID: 1810004.

Narasimhan P, Wood J, Macintyre CR, Mathai D. Risk factors for tuberculosis. *Pulm Med.* 2013;2013:828939. doi: 10.1155/2013/828939. Epub 2013 Feb 12. PMID: 23476764; PMCID: PMC3583136.

Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, Barry PM, Flood J, Mermin JH, Shete PB. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. *PLoS One.* 2021 Apr 1;16(4):e0249012. doi: 10.1371/journal.pone.0249012. PMID: 33793612